• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's After-Market Session

    6/7/24 4:31:12 PM ET
    $AEMD
    $AZTR
    $CPHI
    $RNAZ
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AEMD alert in real time by email

    Gainers

    • Anitra (AMEX:AZTR) stock rose 17.0% to $0.17 during Friday's after-market session. The company's market cap stands at $5.0 million.
    • Scinai Immunotherapeutics (NASDAQ:SCNI) stock increased by 12.79% to $3.35. The company's market cap stands at $1.9 million.
    • Salarius Pharmaceuticals (NASDAQ:SLRX) shares moved upwards by 9.17% to $0.45. The company's market cap stands at $2.1 million.
    • TRACON Pharma (NASDAQ:TCON) stock rose 8.77% to $1.24. The market value of their outstanding shares is at $3.3 million.
    • TransCode Therapeutics (NASDAQ:RNAZ) stock increased by 6.36% to $1.17. The market value of their outstanding shares is at $7.7 million.
    • China Pharma Holdings, Inc. Common Stock (AMEX:CPHI) shares rose 5.64% to $0.28.

    Losers

    • Aethlon Medical (NASDAQ:AEMD) stock fell 7.8% to $0.54 during Friday's after-market session. The company's market cap stands at $2.7 million.
    • Sunshine Biopharma (NASDAQ:SBFM) shares decreased by 7.68% to $0.52. The company's market cap stands at $9.7 million.
    • Tevogen Bio Holdings (NASDAQ:TVGN) shares declined by 6.41% to $0.78. The company's market cap stands at $128.7 million.
    • Rezolute (NASDAQ:RZLT) shares fell 5.95% to $5.38. The market value of their outstanding shares is at $215.9 million.
    • Senti Biosciences (NASDAQ:SNTI) shares declined by 5.92% to $0.26. The company's market cap stands at $12.0 million.
    • Tiziana Life Sciences (NASDAQ:TLSA) shares decreased by 5.01% to $0.95. The market value of their outstanding shares is at $96.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AEMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEMD
    $AZTR
    $CPHI
    $RNAZ

    CompanyDatePrice TargetRatingAnalyst
    Tevogen Bio Holdings Inc.
    $TVGN
    3/4/2026Buy → Hold
    D. Boral Capital
    Rezolute Inc.
    $RZLT
    12/11/2025$2.00Buy → Hold
    Craig Hallum
    Rezolute Inc.
    $RZLT
    12/11/2025Overweight → Neutral
    Cantor Fitzgerald
    Rezolute Inc.
    $RZLT
    12/11/2025$1.00Outperform → Neutral
    Wedbush
    Senti Biosciences Inc.
    $SNTI
    10/14/2025$12.00Buy
    H.C. Wainwright
    Aethlon Medical Inc.
    $AEMD
    7/7/2025$1.50Neutral
    H.C. Wainwright
    Senti Biosciences Inc.
    $SNTI
    6/6/2025$5.00Buy
    Laidlaw
    Tevogen Bio Holdings Inc.
    $TVGN
    3/4/2025$10.00Buy
    D. Boral Capital
    More analyst ratings

    $AEMD
    $AZTR
    $CPHI
    $RNAZ
    SEC Filings

    View All

    SEC Form 6-K filed by Scinai Immunotherapeutics Ltd.

    6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

    3/19/26 10:08:08 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 8-K filed by Aethlon Medical Inc.

    8-K - AETHLON MEDICAL INC (0000882291) (Filer)

    3/17/26 9:15:09 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Azitra Inc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

    8-K - Azitra, Inc. (0001701478) (Filer)

    3/13/26 5:26:35 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $AZTR
    $CPHI
    $RNAZ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hogenhuis Wladimir bought $9,548 worth of shares (5,650 units at $1.69), increasing direct ownership by 5% to 119,675 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    12/17/25 4:14:55 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Roberts Brian Kenneth bought $47,600 worth of shares (28,000 units at $1.70), increasing direct ownership by 10% to 308,352 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    12/17/25 4:13:53 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO Evans Daron bought $79,578 worth of shares (45,000 units at $1.77), increasing direct ownership by 11% to 415,900 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    12/15/25 7:35:57 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $AZTR
    $CPHI
    $RNAZ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Cerrone Gabriele M

    3 - Tiziana Life Sciences Ltd (0001723069) (Issuer)

    3/18/26 9:18:18 PM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by Scinai Immunotherapeutics Ltd.

    3 - Scinai Immunotherapeutics Ltd. (0001611747) (Issuer)

    3/18/26 10:08:31 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by Scinai Immunotherapeutics Ltd.

    3 - Scinai Immunotherapeutics Ltd. (0001611747) (Issuer)

    3/18/26 10:06:28 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEMD
    $AZTR
    $CPHI
    $RNAZ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $AEMD
    $AZTR
    $CPHI
    $RNAZ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026

    JERUSALEM, March 19, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, and the owner of Scinai Biopharma Services Ltd., a rapidly expanding contract development and manufacturing organization (CDMO) serving biotechnology and pharmaceutical companies, today announced its participation in BIO-Europe Spring® 2026, taking place March 23–25 in Lisbon, Portugal. This will be Scinai's first major international conference following its recent acquisition of Recipharm Israel and strategic collaboration with Recipharm, marking a significant expansion of its development and manufact

    3/19/26 7:50:00 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)

    WARREN, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, will speak at the Microsoft Fabric Community Conference (FabCon 2026), taking place March 16–20, 2026, in Atlanta, Georgia. Mr. Mehta will participate in two sessions focused on the evolving intersection of data engineering and artificial intelligence: From Risk to Reward: Modernizing the Data Estate to Power Enterprise AIWednesday, March 18, 4:30PM – 5:05PM alongside Dipti Borkar, VP & GM OneLake & ISVs at Microsoft and Tripti Sethi, Data & AI Lead at Avanade.Agentic Data Engineering on Micr

    3/18/26 12:22:11 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price

    JERUSALEM, March 16, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai" or the "Company"), today announced that it received a written notification from the Nasdaq Listing Qualifications Department on March 12, 2026 indicating that the Company is not in compliance with the Nasdaq Capital Market's minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the American Depositary Shares ("ADSs") was below $1.00 per share for 30 consecutive business days. The notification has no immediate effect on the listing or trading of the ADSs on the Nasdaq Capital Market.In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has

    3/16/26 4:05:00 PM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tevogen Bio downgraded by D. Boral Capital

    D. Boral Capital downgraded Tevogen Bio from Buy to Hold

    3/4/26 9:36:27 AM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Rezolute downgraded by Craig Hallum with a new price target

    Craig Hallum downgraded Rezolute from Buy to Hold and set a new price target of $2.00

    12/11/25 3:51:30 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Rezolute from Overweight to Neutral

    12/11/25 12:30:42 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $AZTR
    $CPHI
    $RNAZ
    Leadership Updates

    Live Leadership Updates

    View All

    Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform

    WARREN, N.J., March 11, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today issued a statement from Founder and CEO Dr. Ryan Saadi regarding the company's progress in developing TVGN 489 for Long COVID, timed with International Long COVID Awareness Month. Following the appointment of a new leadership team on March 9, 2026, Tevogen is accelerating its "Biotech" and "Digital Health" verticals to move TVGN 489 into its next clinical phase. The company is currently evaluating the acquisition of Sciometrix and its Clinicus platform to provide real-world monitoring for Long COVID patients. Tevogen continues to prioritize the development of TVGN 489,

    3/11/26 3:15:00 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tevogen Names Leadership Team to Execute Diversified Growth Strategy

    WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced the appointment of interim leaders across its core business verticals to execute the first phase of its diversified growth strategy. In this first phase, Tevogen is evaluating strategic opportunities that, if completed, are expected to operate as subsidiaries of the Company and could collectively generate annual revenues exceeding $50 million. The Company expects these transactions to close by the second quarter of 2026, subject to customary due diligence and definitive agreements. Leadership Designations: Digital Health: Arpita Patel and Wojtek StobinskiGene

    3/9/26 7:45:00 AM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aethlon Medical to Present on the Emerging Growth Conference on February 25th 2026

    Aethlon invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation on the Emerging Growth Conference.SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that it has been invited to present on the Emerging Growth Conference on February 25, 2026 at 12:30-1:00 PM ET. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO and CFO, Jim Frakes in

    2/23/26 8:01:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    $AZTR
    $CPHI
    $RNAZ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Senti Biosciences Inc.

    SC 13D/A - Senti Biosciences, Inc. (0001854270) (Subject)

    12/4/24 7:08:03 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by TRACON Pharmaceuticals Inc.

    SC 13G/A - Tracon Pharmaceuticals, Inc. (0001394319) (Subject)

    11/14/24 8:51:58 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Rezolute Inc.

    SC 13G/A - Rezolute, Inc. (0001509261) (Subject)

    11/14/24 6:59:50 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $AZTR
    $CPHI
    $RNAZ
    Financials

    Live finance-specific insights

    View All

    Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization

    Lead investor confirmed his intention to maintain his current shareholdings.Company does not anticipate using more than 1% of our authorized shares, including placement through the ATM, over the next 12 months or until the company becomes cash-flow positive.Approximately only one-fifth of total shares outstanding are in the tradable float when accounting for Tevogen's lead investor, directors and named executive officers.Company prioritizing long-term stock-based incentive program aligned with company milestones.Board of Directors continues to evaluate the potential declaration of a one-time special cash dividend to shareholders.Company continues to evaluate acquisitions that could generate

    3/13/26 2:45:00 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, will present at the Leerink Partners 2026 Global Healthcare Conference in Miami, FL on Monday, March 9, 2026, at 2:20 PM ET. A webcast replay will be available on the Events page of the Investors section of the Company's website (sentibio.com). Interested parties may access the live video webcast here. About Senti Bio Senti Bio is a biotechnolog

    3/3/26 9:05:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference

    SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, will highlight the Company's Gene Circuit technology platform, pipeline progress and strategic priorities, with an emphasis on opportunities for partnership across investment, research and development, manufacturing and clinical collaboration at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, from 3:10 – 3:40 PM ET. Live au

    2/24/26 9:15:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care